$-0.41 EPS Expected for AEterna Zentaris Inc. (USA) (AEZS); United Therapeutics (UTHR) Covered By 2 Bulls

October 21, 2017 - By Nellie Frank

Analysts expect AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) to report $-0.41 EPS on November, 14.They anticipate $0.20 EPS change or 32.79% from last quarter’s $-0.61 EPS. After having $-0.46 EPS previously, AEterna Zentaris Inc. (USA)’s analysts see -10.87% EPS growth. The stock increased 0.99% or $0.02 on October 20, reaching $2.03. About 168,187 shares traded. AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has declined 74.02% since October 21, 2016 and is downtrending. It has underperformed by 90.72% the S&P500.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics had 22 analyst reports since July 29, 2015 according to SRatingsIntel. Ladenburg Thalmann upgraded the stock to “Buy” rating in Friday, October 28 report. The company was downgraded on Thursday, January 19 by Standpoint Research. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Buy” rating by Oppenheimer on Tuesday, July 18. As per Thursday, December 15, the company rating was initiated by Oppenheimer. As per Friday, April 29, the company rating was downgraded by Ladenburg Thalmann. Barclays Capital downgraded the stock to “Underweight” rating in Tuesday, November 29 report. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, July 29 report. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Sell” rating by Jefferies on Sunday, August 13. The rating was maintained by Barclays Capital on Friday, February 26 with “Equal-Weight”. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Hold” rating given on Tuesday, May 24 by Argus Research. See United Therapeutics Corporation (NASDAQ:UTHR) latest ratings:

14/09/2017 Broker: Jefferies Rating: Sell New Target: $105.0 Maintain
13/08/2017 Broker: Jefferies Rating: Sell New Target: $105.0000 Maintain
30/07/2017 Broker: Oppenheimer Rating: Buy New Target: $175.0000 Maintain
28/07/2017 Broker: H.C. Wainwright Rating: Hold New Target: $95.0000 Maintain
27/07/2017 Broker: Cowen & Co Rating: Hold New Target: $123.0000 Maintain
18/07/2017 Broker: Oppenheimer Rating: Buy New Target: $175.0000 Maintain
06/06/2017 Broker: Jefferies Rating: Sell New Target: $105.0000 Maintain

Among 3 analysts covering Aeterna Zentaris Inc. (NASDAQ:AEZS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aeterna Zentaris Inc. had 10 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has “Buy” rating given on Wednesday, July 19 by Maxim Group. The firm earned “Buy” rating on Wednesday, July 5 by H.C. Wainwright. Maxim Group maintained it with “Buy” rating and $10 target in Tuesday, January 17 report. As per Friday, June 30, the company rating was maintained by Maxim Group. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, November 24. The stock of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) has “Buy” rating given on Monday, November 9 by Canaccord Genuity. As per Monday, November 23, the company rating was maintained by Maxim Group. On Friday, August 11 the stock rating was maintained by Maxim Group with “Buy”. H.C. Wainwright maintained AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) on Wednesday, December 2 with “Buy” rating.

Aeterna Zentaris Inc is a specialty biopharmaceutical firm engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The company has market cap of $33.24 million. The Firm operates through the biopharmaceutical segment. It currently has negative earnings. The Firm is engaged in drug development activities and in the promotion of products for others.

Since May 4, 2017, it had 0 insider purchases, and 7 sales for $1.09 million activity. ROTHBLATT MARTINE A also sold $156,405 worth of United Therapeutics Corporation (NASDAQ:UTHR) shares.

The stock increased 1.64% or $1.95 on October 20, reaching $121.01. About 402,257 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since October 21, 2016 and is uptrending. It has underperformed by 6.92% the S&P500.

United Therapeutics Corporation is a biotechnology company. The company has market cap of $5.26 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has a 14.1 P/E ratio. The Firm markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension : Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com